Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Inventiva S.A. (IVA:NASDAQ), powered by AI.
Inventiva S.A. is currently trading at $3.58. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Inventiva S.A. on Alpha Lenz.
Inventiva S.A.'s P/E ratio is -1.9.
“Inventiva S.A. trades at a P/E of -1.9 (undervalued) with strong ROE of 524.0%.”
Ask for details →Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. With its research and development headquarters situated in France, the company dedicates its efforts to designing treatments for diseases with significant unmet medical needs, particularly in the fields of oncology, fibrosis, and genetic diseases. A key aspect of Inventiva's strategy involves utilizing its deep expertise in the field of nuclear receptor biology and transcription factors to develop innovative medicines. Inventiva also applies its proprietary technologies to facilitate the discovery of novel candidates through sophisticated screening techniques and biological assays. The company plays a notable role in the pharmaceutical sector, engaging in collaborations with leading global healthcare entities to expedite drug development processes. By advancing promising drug candidates through clinical trials, Inventiva aims to bring transformative therapies to the market, ultimately enhancing patient care and addressing critical health challenges globally. The significance of their work is underscored by the potential impact on treatment paradigms for diseases currently lacking effective therapeutic options.
“Inventiva S.A. trades at a P/E of -1.9 (undervalued) with strong ROE of 524.0%.”
Ask for details →Inventiva S.A. (ticker: IVA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 84 employees. Market cap is $667M.
The current price is $3.58 with a P/E ratio of -1.88x and P/B of -23.39x.
ROE is 523.99% and operating margin is -2964.15%. Annual revenue is $4M.